Literature DB >> 1738092

HIV-1 infection of human fetal thymocytes.

K E Tanaka1, W C Hatch, Y Kress, R Soeiro, T Calvelli, W K Rashbaum, A Rubinstein, W D Lyman.   

Abstract

Some neonates with congenital human immunodeficiency virus type 1 (HIV-1) infection exhibit immune dysregulation. This suggests that fetal CD4+ cells, possibly thymocytes, may be infected during gestation. If thymocytes are infected, this may result in a disruption of T-cell differentiation. To examine this hypothesis, normal human fetal thymocytes were established in tissue culture, characterized, and then exposed to HIV-1. On initial isolation, fetal thymocytes were analyzed for phenotypic markers by flow cytometry and assessed for T-cell function by mitogen-stimulated thymidine incorporation. The thymocytes comprised greater than 70% double positive (CD4+, CD8+) cells and responded to T- but not to B-cell mitogens. Thereafter, thymocytes were incubated in either tissue culture medium containing infectious HIV-1 or in control (HIV-free) medium. Infection of fetal thymocytes was determined by light and electron microscopy in combination with immunocytochemistry, molecular hybridization, and an infectious cell center (ICC) assay. After 1 week in culture, the thymocytes exposed to HIV-1 were positive by immunocytochemistry for the HIV-1-associated protein gp41. In addition, the presence of HIV-1 DNA was detected by molecular hybridization confirming infection of these cells. The ICC assay demonstrated the production of infectious HIV-1 particles and budding of mature virions was observed by electron microscopy. These studies demonstrate that human fetal thymocytes can be infected with HIV-1 in vitro and that this infection results in production of infectious virions. These results support the hypothesis that vertical transmission of HIV-1 in vivo may result in the infection of fetal thymocytes, which may contribute to postnatal HIV-1-associated pathologic conditions.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1738092

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  7 in total

1.  Clinico-Immunological Profile of Children Infected with HIV Through Vertical Transmission, in Southern India.

Authors:  Praveen R Shahapur; Indira Bairy
Journal:  J Clin Diagn Res       Date:  2014-06-20

2.  Rapid and irreversible CD4+ T-cell depletion induced by the highly pathogenic simian/human immunodeficiency virus SHIV(DH12R) is systemic and synchronous.

Authors:  Tatsuhiko Igarashi; Charles R Brown; Russell A Byrum; Yoshiaki Nishimura; Yasuyuki Endo; Ronald J Plishka; Charles Buckler; Alicia Buckler-White; Georgina Miller; Vanessa M Hirsch; Malcolm A Martin
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

3.  Thymocyte-thymic epithelial cell interaction leads to high-level replication of human immunodeficiency virus exclusively in mature CD4(+) CD8(-) CD3(+) thymocytes: a critical role for tumor necrosis factor and interleukin-7.

Authors:  L Chêne; M T Nugeyre; E Guillemard; N Moulian; F Barré-Sinoussi; N Israël
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

Review 4.  Envelope glycoproteins of human immunodeficiency virus type 1: profound influences on immune functions.

Authors:  N Chirmule; S Pahwa
Journal:  Microbiol Rev       Date:  1996-06

5.  Contact with thymic epithelial cells as a prerequisite for cytokine-enhanced human immunodeficiency virus type 1 replication in thymocytes.

Authors:  M Rothe; L Chêne; M T Nugeyre; J Braun; F Barré-Sinoussi; N Israël
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

6.  High-level replication of human immunodeficiency virus in thymocytes requires NF-kappaB activation through interaction with thymic epithelial cells.

Authors:  L Chêne; M T Nugeyre; F Barré-Sinoussi; N Israël
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

7.  Two subpopulations of human triple-negative thymic cells are susceptible to infection by human immunodeficiency virus type 1 in vitro.

Authors:  H Valentin; M T Nugeyre; F Vuillier; L Boumsell; M Schmid; F Barré-Sinoussi; R A Pereira
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.